09:14 AM EDT, 06/17/2024 (MT Newswires) -- Zymeworks ( ZYME ) said on Monday that the US Food and Drug Administration has cleared the investigational new drug application for its experimental therapy, ZW171, to treat mesothelin-expressing cancers.

"We look forward to initiating clinical development of ZW171 during 2024 and continuing to advance additional product candidates in our '5 by 5' strategy over the next 24 months," said Paul Moore, chief scientific officer of Zymeworks ( ZYME ).

The drug developer expects to file applications seeking regulatory permission to commence clinical studies for ZW171 in other non-US jurisdictions in H2 2024.

Shares of Zymeworks ( ZYME ) were more than 6% higher in premarket trading.

Price: 9.62, Change: +0.58, Percent Change: +6.42